Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL
A multicenter, prospective trial to evaluate the efficacy and safety of Selinexor, anti-PD-1 antibody plus Golidocitinib in the treatment of relapsed or refractory Natural Killer / T-cell lymphoma.
Lymphoma, Extranodal NK-T-Cell
DRUG: Selinexor, anti-PD-1 antibody plus Golidocitinib
Best CRR, CRR defined according to 2014 Lugano criteria and 2016 Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy., through study completion, an average of 1 year
This study aims to evaluate the efficacy and safety of Selinexor, anti-PD-1 antibody plus Golidocitinib in relapsed or refractory NKTCL and find the optimal treatment regimen for patients with relapsed refractory NKTCL.

Patients receive 3 cycles of Selinexor, anti-PD-1 antibody plus Golidocitinib and then PET evaluation.